Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/28/2008

ward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
2. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. ThreeWire Expands Presence in the Pharmaceutical Arena
5. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
10. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Seahorse ... cell metabolism, is the provider of XF Technology ... all disease research areas. As the links between ... into cell metabolism is escalating rapidly.   ... by the Nature Publishing Group (NPG) featuring XF ...
(Date:7/28/2015)... -- Research and Markets ( ... "Analysis of the Global Flow Cytometry Market ... Globally, flow cytometry remains a popular tool for ... stem cells. But the market is witnessing active ... from underdeveloped nations to quantitate CD4 cell markers ...
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering ... credentialing course to local area veterinarians. , The tour and course will be given ... no charge) at VetStem’s Poway facility. Staff members are welcome to attend with their ...
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, ... diversified life sciences company, today announced that its stockholders ... of common stock of the Company from 1,000,000,000 to ... July 27, 2015 at the Law Offices of Nixon ... the Special Meeting, there were 480,655,929 shares of common ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3
... Opportunities in Transplant Diagnostics, Genetic Testing and Pharmaceutical ... 8 Gen-Probe (Nasdaq: GPRO ) ... acquisition of Tepnel Life Sciences, plc, a rapidly ... in the United Kingdom, for 27.1 pence ($0.40)(1) ...
... (TSX-V: ENW) ("EnWave" or "the Company") today announced ... developed powderREV technology in the dehydration of cultures ... tests were conducted as the first phase of ... objective of the agreement is to create a ...
... 7 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals,Inc. ("Biostar" or the "Company") (OTC Bulletin Board: ... , , Highlights for Year Ended December 31, 2008:, ... million, up from $15.9 million, for ... to $6,690,542 as compared to, $3,963,524 ...
Cached Biology Technology:Gen-Probe Completes Acquisition of Tepnel Life Sciences 2Gen-Probe Completes Acquisition of Tepnel Life Sciences 3Gen-Probe Completes Acquisition of Tepnel Life Sciences 4EnWave Announces Collaboration and Initial Testing Results with Danisco AS 2EnWave Announces Collaboration and Initial Testing Results with Danisco AS 3Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 2Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 3Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 4Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 5Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 6
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Eighty percent of American voters favor national standards that ... la carte foods sold in U.S. schools and encourage the ... a new poll commissioned by the Kids, Safe & Healthful ... and the Robert Wood Johnson Foundation. The U.S. ...
... this month on ecological changes at 26 global research sites ... in the high mountains west of the city -- indicates ... most sensitive to changes in climate. The six ... The papers were tied to data gathered at sites ...
... Academy of Sciences will host the Fifth Annual ... design of oligosaccharides and proteins for materials and ... on the following areas: (1) synthetic and biosynthetic ... these macromolecules in materials science and glycobiology, (2) ...
Cached Biology News:Poll shows strong voter support for school nutrition standards 2Poll shows strong voter support for school nutrition standards 3CU research shows warming climate threatens ecology at mountain research site west of Boulder 2CU research shows warming climate threatens ecology at mountain research site west of Boulder 3
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
SCP-1 (P-17)...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: